Tiziana Life Sciences Ltd
TLSA
$0.81
$0.00991.24%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 45.99% | 45.99% | 16.63% | 16.63% | -90.94% |
| Total Depreciation and Amortization | 12.73% | 12.73% | -10.87% | -10.87% | 1,000.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.29% | 40.29% | -54.80% | -54.80% | 142.22% |
| Change in Net Operating Assets | 132.46% | 132.46% | 449.70% | 449.70% | -185.05% |
| Cash from Operations | 103.51% | 103.51% | 44.09% | 44.09% | 4.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -99,900.00% | -99,900.00% | -- |
| Cash from Investing | -- | -- | -99,900.00% | -99,900.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -86.49% | -86.49% | -49.09% | -49.09% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 68.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 76.29% | 76.29% | 113.76% | 113.76% | 63.99% |
| Foreign Exchange rate Adjustments | -334.18% | -334.18% | 71.16% | 71.16% | -36.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.54% | 99.54% | 35.71% | 35.71% | 26.32% |